Dimensional Fund Advisors LP grew its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 42.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 778,163 shares of the company's stock after buying an additional 232,822 shares during the quarter. Dimensional Fund Advisors LP owned 1.14% of Replimune Group worth $9,425,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in the business. Sterling Capital Management LLC grew its stake in shares of Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Replimune Group by 24.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock valued at $198,000 after purchasing an additional 3,177 shares during the period. SG Americas Securities LLC grew its stake in shares of Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock valued at $318,000 after buying an additional 3,374 shares during the period. Rhumbline Advisers grew its holdings in shares of Replimune Group by 8.3% during the 4th quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock worth $1,156,000 after purchasing an additional 7,317 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Replimune Group by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company's stock valued at $2,733,000 after acquiring an additional 8,074 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.
Replimune Group Price Performance
Shares of NASDAQ:REPL opened at $7.71 on Friday. The business has a 50 day moving average price of $9.36 and a 200 day moving average price of $11.48. The company has a market cap of $593.79 million, a price-to-earnings ratio of -2.51 and a beta of 0.68. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00.
Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Research analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. HC Wainwright boosted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Finally, BMO Capital Markets boosted their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $19.43.
Read Our Latest Stock Analysis on Replimune Group
About Replimune Group
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
